Submit Deal

Douglas Maffei

Vice President, Head of Investor Relations & ESG at SEAGEN INC

Manager

Seattle

Deal Bio

Total Deals5

Valued Deals5

Total Value£56,333M

Avg. Deal Size£11,267M

Market Context

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

Expertise

Key Relationships (5)

Sort

United States

Biotechnology

AcquisitionPublicMajorityTender Offer

target

Forty Seven

bidder

Gilead Sciences

£3,821m

48 dealmakers

United States

Biotechnology

PublicMinorityAcquisition

target

Arcus Biosciences

bidder

Gilead Sciences

£162m

8 dealmakers

United States

Medical Services

AcquisitionMinorityPrivateDomestic

target

Tizona Therapeutics

bidder

Gilead Sciences

£235m

43 dealmakers

United States

Pharmaceuticals

MajorityDomesticPublicAcquisitionTender Offer

target

IMMUNOMEDICS

bidder

Gilead Sciences

£16,407m

50 dealmakers

United States

Biotechnology

MajorityDomesticAcquisitionPublic

target

Seagen

bidder

Pfizer

£35,705m

67 dealmakers

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy